1

HIGHLIGHTS OF PRESCRIBING INFORMATION glucose lowering medications, meal pattern, physical activity; in patients
with renal or hepatic impairment or with hypoglycemia unawareness.
These highlights do not include all the information needed to use (5.3)
HUMULIN R safely and effectively. See full prescribing information for
HUMULIN R. • Hypoglycemia Due to Medication Errors: Accidental mix-ups between
insulin products can occur. Instruct patients to check insulin labels
HUMULIN R (insulin human injection), for subcutaneous or intravenous before injection. (5.4)
use
• Hypersensitivity and Allergic Reactions: Severe, life-threatening,
Initial U.S. Approval: 1982 generalized allergy, including anaphylaxis, can occur. Discontinue
---------------------------- INDICATIONS AND USAGE --------------------------­ HUMULIN R, monitor, and treat if indicated. (5.5)
HUMULIN® R is a short-acting human insulin indicated to improve glycemic • Hypokalemia: May be life-threatening. Monitor potassium levels in
control in adult and pediatric patients with diabetes mellitus. (1) patients at risk for hypokalemia and treat if indicated. (5.6)
• Fluid Retention and Heart Failure with Concomitant Use of
----------------------- DOSAGE AND ADMINISTRATION ---------------------­ Thiazolidinediones (TZDs): Observe for signs and symptoms of heart
• See Full Prescribing Information for important administration failure; consider dosage reduction or discontinuation if heart failure
instructions. (2.1) occurs. (5.7)
• Subcutaneous injection: inject subcutaneously 30 minutes before a meal.
Rotate injection sites to reduce the risk of lipodystrophy. (2.2) ------------------------------- ADVERSE REACTIONS -----------------------------­
• Intravenous infusion: administer intravenously ONLY under medical Adverse reactions observed with HUMULIN R include hypoglycemia,
supervision at concentrations from 0.1 unit/mL to 1 unit/mL in infusion allergic reactions, injection site reactions, lipodystrophy, weight gain, edema,
systems containing 0.9% sodium chloride. (2.2) pruritus, and rash. (6)
• Individualize dose based on route of administration, metabolic needs, To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and
blood glucose monitoring results and glycemic control goal. (2.3) Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088
or www.fda.gov/medwatch.
• HUMULIN R given by subcutaneous injection should generally be used
in regimens with an intermediate- or long-acting insulin. (2.3) ------------------------------- DRUG INTERACTIONS -----------------------------­
• Do not mix with insulin preparations other than HUMULIN® N. (2.5) • Drugs that may increase the risk of hypoglycemia: antidiabetic agents,
ACE inhibitors, angiotensin II receptor blocking agents, disopyramide,
---------------------- DOSAGE FORMS AND STRENGTHS --------------------­ fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline,
Injection: HUMULIN R 100 units per mL (U-100) is available as: pramlintide, propoxyphene, salicylates, somatostatin analog (e.g.,
• 10 mL vials (3) octreotide), and sulfonamide antibiotics (7)
• 3 mL vials (3) • Drugs that may decrease the blood glucose lowering effect: atypical
antipsychotics, corticosteroids, danazol, diuretics, estrogens, glucagon,
-------------------------------CONTRAINDICATIONS-----------------------------­ isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g.,
• Do not use during episodes of hypoglycemia. (4) in oral contraceptives), protease inhibitors, somatropin,
• Do not use in patients with hypersensitivity to HUMULIN R or any of sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and
its excipients. (4) thyroid hormones (7)
• Drugs that may increase or decrease the blood glucose lowering effect:
------------------------ WARNINGS AND PRECAUTIONS ----------------------­ Alcohol, beta-blockers, clonidine, lithium salts, and pentamidine (7)
• Never share needles or syringes with another person. (5.1)
• Drugs that may blunt the signs and symptoms of hypoglycemia: beta-
• Hyper- or Hypoglycemia with Changes in Insulin Regimen: Carry out blockers, clonidine, guanethidine, and reserpine (7)
under close medical supervision and increase frequency of blood glucose
monitoring. (5.2) See 17 for PATIENT COUNSELING INFORMATION and FDA-
approved patient labeling.
• Hypoglycemia: May be life-threatening. Increase frequency of blood Revised: 05/2018
glucose monitoring with changes to: insulin dosage, co-administered

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE 8 USE IN SPECIFIC POPULATIONS

2 DOSAGE AND ADMINISTRATION 8.1 Pregnancy
2.1 Important Administration Instructions 8.2 Lactation
2.2 Route of Administration 8.4 Pediatric Use
2.3 Dosing Instructions 8.5 Geriatric Use
2.4 Dosage Adjustment due to Drug Interactions 8.6 Renal Impairment
2.5 Instructions for Mixing with Other Insulins for Subcutaneous 8.7 Hepatic Impairment
Injection 10 OVERDOSAGE
3 DOSAGE FORMS AND STRENGTHS 11 DESCRIPTION
4 CONTRAINDICATIONS 12 CLINICAL PHARMACOLOGY
5 WARNINGS AND PRECAUTIONS 12.1 Mechanism of Action
5.1 Never Share Needles or Syringes between Patients 12.2 Pharmacodynamics
5.2 Hyperglycemia or Hypoglycemia with Changes in Insulin 12.3 Pharmacokinetics
Regimen 13 NONCLINICAL TOXICOLOGY
5.3 Hypoglycemia 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
5.4 Hypoglycemia Due to Medication Errors 16 HOW SUPPLIED/STORAGE AND HANDLING
5.5 Hypersensitivity and Allergic Reactions 16.1 How Supplied
5.6 Hypokalemia 16.2 Storage and Handling
5.7 Fluid Retention and Heart Failure with Concomitant Use of 16.3 Admixture for Intravenous Administration
PPAR-gamma Agonists
17 PATIENT COUNSELING INFORMATION
6 ADVERSE REACTIONS
*Sections or subsections omitted from the full prescribing information are not
7 DRUG INTERACTIONS listed

Reference ID: 4268906

 FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

HUMULIN R is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.

2 DOSAGE AND ADMINISTRATION

2.1 Important Administration Instructions

• Always check the insulin label before administration to confirm the correct insulin product is being used [see Warnings
and Precautions (5.4)].
• Inspect HUMULIN R visually before use. It should appear clear and colorless. Do not use HUMULIN R if particulate
matter or coloration is seen.

2.2 Route of Administration

Subcutaneous Injection
• Inject HUMULIN R subcutaneously approximately 30 minutes before meals into the thigh, upper arm, abdomen, or
buttocks.
• Rotate injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy [see
Adverse Reactions (6)].
Intravenous Administration
• Administer HUMULIN R intravenously ONLY under medical supervision with close monitoring of blood glucose and
potassium levels to reduce the risk of hypoglycemia and hypokalemia [see Warnings and Precautions (5.3, 5.6), How
Supplied/Storage and Handling (16.3)].
• For intravenous use, HUMULIN R should be used at concentrations from 0.1 unit/mL to 1 unit/mL in infusion systems
containing 0.9% sodium chloride.

2.3 Dosing Instructions

• Individualize and adjust the dosage of HUMULIN R based on the route of administration, the patient’s metabolic needs,
blood glucose monitoring results, and glycemic control goal.
• HUMULIN R given by subcutaneous injection should generally be used in regimens with an intermediate- or long-acting
insulin.
• Dosage adjustments may be needed with changes in physical activity, changes in meal patterns (e.g., macronutrient
content or timing of food intake), changes in renal or hepatic function, or during acute illness [see Warnings and
Precautions (5.2, 5.3), Use in Specific Populations (8.6, 8.7)].
• Dosage adjustment may be needed when switching from another insulin to HUMULIN R [see Warnings and Precautions
(5.2)].

2.4 Dosage Adjustment due to Drug Interactions

• Dosage adjustment may be needed when HUMULIN R is co-administered with certain drugs [see Drug Interactions (7)].

2.5 Instructions for Mixing with Other Insulins for Subcutaneous Injection
• Do not mix HUMULIN R with insulin preparations other than HUMULIN N.
• To mix HUMULIN R and HUMULIN N, draw HUMULIN R into the syringe first. Inject immediately after mixing.

3 DOSAGE FORMS AND STRENGTHS

HUMULIN R injection is 100 units per mL (U-100), a clear and colorless solution available as:
• 10 mL vials
• 3 mL vials

4 CONTRAINDICATIONS
HUMULIN R is contraindicated:
• during episodes of hypoglycemia
• in patients with hypersensitivity to HUMULIN R or any of its excipients.

Reference ID: 4268906

 5 WARNINGS AND PRECAUTIONS

5.1 Never Share Needles or Syringes between Patients

Patients using HUMULIN R vials must never share needles or syringes with another person. Sharing poses a risk for
transmission of blood-borne pathogens.

5.2 Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen

Changes in insulin, manufacturer, type, or method of administration may affect glycemic control and predispose to
hypoglycemia [see Warnings and Precautions (5.3)] or hyperglycemia. These changes should be made cautiously and only under
medical supervision and the frequency of blood glucose monitoring should be increased. For patients with type 2 diabetes, adjustments
in concomitant anti-diabetic medications may be needed.

5.3 Hypoglycemia
Hypoglycemia is the most common adverse reaction of all insulins, including HUMULIN R. Severe hypoglycemia can cause
seizures, may lead to unconsciousness, may be life threatening or cause death. Hypoglycemia can impair concentration ability and
reaction time; this may place an individual and others at risk in situations where these abilities are important (e.g., driving or operating
other machinery).
Hypoglycemia can happen suddenly and symptoms may differ in each individual and change over time in the same individual.
Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes, in patients with diabetic
nerve disease, in patients using medications that block the sympathetic nervous system (e.g., beta-blockers) [see Drug Interactions
(7)], or in patients who experience recurrent hypoglycemia.
Risk Factors for Hypoglycemia
The risk of hypoglycemia after an injection is related to the duration of action of the insulin and, in general, is highest when
the glucose lowering effect of the insulin is maximal. As with all insulin preparations, the glucose lowering effect time course of
HUMULIN R may vary in different individuals or at different times in the same individual and depends on many conditions, including
the area of injection as well as the injection site blood supply and temperature [see Clinical Pharmacology (12.2)].
Other factors which may increase the risk of hypoglycemia include changes in meal pattern (e.g., macronutrient content or
timing of meals), changes in level of physical activity, or changes to co-administered medication [see Drug Interactions (7)]. Patients
with renal or hepatic impairment may be at higher risk of hypoglycemia [see Use in Specific Populations (8.6, 8.7)].
Risk Mitigation Strategies for Hypoglycemia
Patients and caregivers must be educated to recognize and manage hypoglycemia. Self-monitoring of blood glucose plays an
essential role in the prevention and management of hypoglycemia. In patients who have reduced symptomatic awareness of
hypoglycemia, increased frequency of blood glucose monitoring is recommended.

5.4 Hypoglycemia Due to Medication Errors

Accidental mix-ups between HUMULIN R and other insulins have been reported. To avoid medication errors between
HUMULIN R and other insulins, instruct patients to always check the insulin label before each injection.

5.5 Hypersensitivity and Allergic Reactions

Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with HUMULIN R [see Adverse Reactions (6)].
If hypersensitivity reactions occur, discontinue HUMULIN R; treat per standard of care and monitor until symptoms and signs
resolve. HUMULIN R is contraindicated in patients who have had a hypersensitivity reaction to HUMULIN R or its excipients [see
Contraindications (4)].

5.6 Hypokalemia
All insulin products, including HUMULIN R, cause a shift in potassium from the extracellular to intracellular space, possibly
leading to hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium
levels in patients at risk for hypokalemia if indicated (e.g., patients using potassium-lowering medications, patients taking medications
sensitive to serum potassium concentrations).

5.7 Fluid Retention and Heart Failure with Concomitant Use of PPAR-gamma Agonists
Thiazolidinediones (TZDs), which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists, can cause dose-
related fluid retention, particularly when used in combination with insulin. Fluid retention may lead to or exacerbate heart failure.
Patients treated with insulin, including HUMULIN R, and a PPAR-gamma agonist should be observed for signs and symptoms of
heart failure. If heart failure develops, it should be managed according to current standards of care, and discontinuation or dose
reduction of the PPAR-gamma agonist must be considered.

Reference ID: 4268906

 6 ADVERSE REACTIONS
The following adverse reactions are also discussed elsewhere in the labeling:
• Hypoglycemia [see Warnings and Precautions (5.3)]
• Medication Errors [see Warnings and Precautions (5.4)]
• Hypersensitivity [see Warnings and Precautions (5.5)]
• Hypokalemia [see Warnings and Precautions (5.6)]
Adverse Reactions from Clinical Studies or Postmarketing Reports
The following additional adverse reactions have been identified during clinical studies or from postmarketing reports with use
of HUMULIN R. Because some of these reactions are reported voluntarily from a population of uncertain size, it is not always
possible to reliably estimate their frequency or to establish a causal relationship to drug exposure.
Adverse reactions associated with insulin initiation and glucose control intensification
Intensification or rapid improvement in glucose control has been associated with a transitory, reversible ophthalmologic
refraction disorder, worsening of diabetic retinopathy, and acute painful peripheral neuropathy. Over the long-term, improved
glycemic control decreases the risk of diabetic retinopathy and neuropathy.
Hypersensitivity Reactions
Severe allergic reactions may include anaphylaxis, generalized skin reactions, rash, angioedema, bronchospasm, hypotension,
and shock.
Hypoglycemia
Hypoglycemia is the most commonly observed adverse reaction in HUMULIN R.
Hypokalemia
HUMULIN R can cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia.
Injection Site Reactions
Injection site reactions may include injection site hematoma, pain, hemorrhage, erythema, nodules, swelling, discoloration,
pruritus, warmth, and injection site mass.
Lipodystrophy
Administration of insulin subcutaneously, including HUMULIN R, has resulted in lipoatrophy (depression in the skin) or
lipohypertrophy (enlargement or thickening of tissue) in some patients [see Dosage and Administration (2.2)].
Medication Errors
Medication errors in which other insulins have been accidentally substituted for HUMULIN R have been identified during
postapproval use.
Peripheral Edema
Insulin, including HUMULIN R, may cause sodium retention and edema, particularly if previously poor metabolic control is
improved by intensified insulin therapy.
Weight Gain
Weight gain can occur with insulin therapy, including HUMULIN R, and has been attributed to the anabolic effects of insulin.
Immunogenicity
As with all therapeutic peptides, insulin administration may cause anti-insulin antibodies to form. The incidence of antibody
formation with HUMULIN R is unknown.

7 DRUG INTERACTIONS

Table 1: Clinically Significant Drug Interactions with HUMULIN R

Drugs that May Increase the Risk of Hypoglycemia
Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates,
fluoxetine, monoamine oxidase inhibitors, propoxyphene, pentoxifylline, pramlintide, salicylates,
somatostatin analog (e.g., octreotide), and sulfonamide antibiotics
Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when HUMULIN R is
co-administered with these drugs.
Drugs that May Decrease the Blood Glucose Lowering Effect of HUMULIN R
Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens,
glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral
contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine,
terbutaline), and thyroid hormones.

Reference ID: 4268906

 Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when HUMULIN R is
co-administered with these drugs.
Drugs that May Increase or Decrease the Blood Glucose Lowering Effect of HUMULIN R
Drugs: Alcohol, beta-blockers, clonidine, and lithium salts. Pentamidine may cause hypoglycemia, which may
sometimes be followed by hyperglycemia.
Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when HUMULIN R is
co-administered with these drugs.
Drugs that May Blunt Signs and Symptoms of Hypoglycemia
Drugs: Beta-blockers, clonidine, guanethidine, and reserpine
Intervention: Increased frequency of glucose monitoring may be required when HUMULIN R is co-administered with
these drugs.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy
Risk Summary
Available data from published studies over decades have not established an association with human insulin use during
pregnancy and major birth defects, miscarriage, or adverse maternal or fetal outcomes (see Data). There are risks to the mother and
fetus associated with poorly controlled diabetes in pregnancy (see Clinical Considerations). Animal reproduction studies were not
performed.
The estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a HbA1c >7% and
has been reported to be as high as 20-25% in women with a HbA1c >10%. The estimated background risk of miscarriage for the
indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage
in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
Clinical Considerations
Disease-associated maternal and/or embryo/fetal risk
Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous
abortions, preterm delivery, stillbirth, and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth
defects, stillbirth, and macrosomia-related morbidity.
Data
Human Data
While available studies cannot definitively establish the absence of risk, published data from retrospective studies, open-label,
randomized, parallel studies and meta-analyses over decades have not established an association with human insulin use during
pregnancy and major birth defects, miscarriage, or adverse maternal or fetal outcomes. All available studies have methodological
limitations, including lack of blinding, unclear methods or randomization, and small sample size.

8.2 Lactation
Risk Summary
Available data from published literature suggests that exogenous human insulin products, including HUMULIN R, are
transferred into human milk. There are no adverse reactions reported in breastfed infants in the literature. There are no data on the
effects of exogenous human insulin products, including HUMULIN R on milk production. The developmental and health benefits of
breastfeeding should be considered along with the mother's clinical need for HUMULIN R and any potential adverse effects on the
breastfed child from HUMULIN R or from the underlying maternal condition.

8.4 Pediatric Use

HUMULIN R is indicated to improve glycemic control in pediatric patients with diabetes mellitus.
The dosage of HUMULIN R must be individualized in pediatric patients based on metabolic needs and frequent monitoring of
blood glucose to reduce the risk of hypoglycemia [see Dosage and Administration (2.3), Warnings and Precautions (5.3)].

8.5 Geriatric Use

The effect of age on the pharmacokinetics and pharmacodynamics of HUMULIN R has not been studied. Elderly patients
using HUMULIN R may be at increased risk of hypoglycemia due to co-morbid disease [see Warnings and Precautions (5.3)].

8.6 Renal Impairment

Reference ID: 4268906

 The effect of renal impairment on the pharmacokinetics and pharmacodynamics of HUMULIN R has not been studied.
Patients with renal impairment are at increased risk of hypoglycemia and may require more frequent HUMULIN R dose adjustment
and more frequent blood glucose monitoring [see Warnings and Precautions (5.3)].

8.7 Hepatic Impairment

The effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of HUMULIN R has not been studied.
Patients with hepatic impairment are at increased risk of hypoglycemia and may require more frequent HUMULIN R dose adjustment
and more frequent blood glucose monitoring [see Warnings and Precautions (5.3)].

10 OVERDOSAGE
Excess insulin administration may cause hypoglycemia and hypokalemia. Mild episodes of hypoglycemia usually can be
treated with oral glucose. Adjustments in drug dosage, meal patterns, or exercise may be needed. More severe episodes with coma,
seizure, or neurologic impairment may be treated with intramuscular or subcutaneous glucagon or intravenous glucose. Sustained
carbohydrate intake and observation may be necessary because hypoglycemia may recur after apparent clinical recovery.
Hypokalemia must be corrected appropriately [see Warnings and Precautions (5.3, 5.6)].

11 DESCRIPTION
HUMULIN R (insulin human injection) is a short-acting human insulin for subcutaneous or intravenous use. HUMULIN R is
produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli. HUMULIN R is regular
human insulin and has the empirical formula C257H383N65O77S6 with a molecular weight of 5808.
HUMULIN R is a sterile, aqueous, clear, and colorless solution. HUMULIN R contains 100 units of insulin in each milliliter.
Each milliliter of HUMULIN R also contains glycerin 16 mg, metacresol 2.5 mg, endogenous zinc (approximately
0.015 mg/100 units,) and Water for Injection. Sodium hydroxide and hydrochloric acid may be added during manufacture to adjust the
pH.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

The primary activity of insulin, including HUMULIN R, is the regulation of glucose metabolism. Insulin lowers blood glucose
by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin
inhibits lipolysis and proteolysis, and enhances protein synthesis.

12.2 Pharmacodynamics
The time course of insulin action (i.e., glucose lowering) may vary considerably in different individuals or within the same
individual. With subcutaneous use, the pharmacologic effect of HUMULIN R begins approximately 30 minutes (range: 10 to 75
minutes) after administration of doses in the 0.05 to 0.4 units/kg range (Figure 1). The effect is maximal at approximately 3 hours
(range: 20 minutes to 7 hours) and terminates after approximately 8 hours (range: 3 to 14 hours). In a study that administered 50 and
100 units doses subcutaneously to obese subjects, mean time of termination of effect was prolonged to approximately 18 hours (range
approximately 12-24 hours).

Figure 1: Mean Insulin Activity Versus Time Profile After Subcutaneous Injection of HUMULIN R (0.3 unit/kg) in Healthy
Subjects.

Reference ID: 4268906

 With intravenous use, the pharmacologic effect of HUMULIN R begins at approximately 10 to 15 minutes and terminates at a
median time of approximately 4 hours (range: 2 to 6 hours) after administration of doses in the range of 0.1 to 0.2 units/kg.
The intravenous administration of HUMULIN R was tested in 21 people with type 1 diabetes. During the 6-hour assessment
phase patients received intravenous HUMULIN R at an initial dose of 0.5 units/hour, adjusted to maintain blood glucose
concentrations near normoglycemia (100 to 160 mg/dL).
The mean blood glucose levels during the assessment phase for patients on HUMULIN R therapy are summarized below in
Table 2. All patients achieved near normoglycemia during the 6-hour assessment phase. The average time (± SE) required to attain
near normoglycemia was 161 ± 14 minutes for HUMULIN R.

Table 2: Mean Blood Glucose Concentrations (mg/dL) during Intravenous Infusions of HUMULIN R
Time from Start of Infusion (minutes) Mean Blood Glucose (mg/dL) Intravenousa
0 220 ± 11
30 204 ± 17
60 193 ± 18
120 172 ± 28
180 153 ± 30
240 139 ± 24
300 131 ± 22
360 128 ± 18
a
Results shown as mean ± Standard Deviation.

12.3 Pharmacokinetics
Absorption — In healthy subjects given subcutaneous doses of HUMULIN R ranging from 0.05 to 0.4 unit/kg, mean peak
serum levels occurred between 36 to 150 minutes after dosing. After subcutaneous administration of a single 12 unit dose
(approximately 0.15 units/kg) to patients with type 1 diabetes, the median peak serum level occurred at approximately 2 hours (range:
20 minutes-6 hours). In a study that administered 50 units (0.4-0.6 unit/kg) and 100 units (0.8-1.3 unit/kg) doses subcutaneously to
healthy obese subjects, median peak serum levels were prolonged to approximately 3 hours (range 1 to 8 hours). The absolute
bioavailability after a single subcutaneous injection of HUMULIN R ranges from 48% to 89% in the 0.1 to 0.3 unit/kg dose range.
Distribution — When HUMULIN R is administered intravenously at doses of 0.1 or 0.2 unit/kg, the mean volume of
distribution ranges between 0.32 to 0.67 L/kg.
Metabolism — The uptake and degradation of insulin occurs predominantly in liver, kidney, muscle, and adipocytes, with the
liver being the major organ involved in the clearance of insulin.
Excretion — After subcutaneous administration of HUMULIN R doses in the 0.05-0.4 unit/kg dose range, the median
apparent half-life is approximately 1.5 hours (range: 40 minutes-7 hours). Mean apparent half-life of HUMULIN R after subcutaneous
administration of higher doses (50 and 100 units) to healthy obese subjects was approximately 3.6 hours (range= 1.6-8.6 hours).
When administered intravenously, HUMULIN R had a mean half-life of approximately 20 minutes at a 0.1 unit/kg dose and 1
hour at a 0.2 unit/kg dose.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenicity and fertility studies were not performed in animals.

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

HUMULIN R injection is 100 units per mL (U-100), a clear and colorless solution available as:
10 mL vials NDC 0002-8215-01
3 mL vials NDC 0002-8215-17
Patients using HUMULIN R vials must never share needles or syringes with another person.

16.2 Storage and Handling

Protect from heat and light. Do not freeze. Do not use HUMULIN R after the expiration date printed on the label or if it has
been frozen.

Reference ID: 4268906

 Table 3. Storage Conditions and Expiration Dates for HUMULIN R

Not In-Use (Unopened) Not In-Use (Unopened) In-Use (Opened)

Refrigerated Room Temperature Refrigerated or
(36° to 46°F [2° to 8°C]) (below 86°F [30°C]) Room Temperature
10 mL vial Until expiration date 31 days 31 days
3 mL vial

16.3 Admixture for Intravenous Administration

Intravenous infusion bags prepared with HUMULIN R are stable when stored in a refrigerator (36° to 46°F [2° to 8°C]) for 48
hours and then may be used at room temperature for up to an additional 48 hours [see Dosage and Administration (2.2)].

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

Never Share Needles or Syringes between Patients

Advise patients using HUMULIN R vials not to share needles or syringes with another person. Sharing poses a risk for
transmission of blood-borne pathogens.

Hypoglycemia
Inform patients that hypoglycemia is the most common adverse reaction with insulin. Instruct patients on self-management
procedures including glucose monitoring, proper injection technique, and management of hypoglycemia and hyperglycemia,
especially at initiation of HUMULIN R therapy. Instruct patients on handling of special situations such as intercurrent conditions
(illness, stress, or emotional disturbances), an inadequate or skipped insulin dose, inadvertent administration of an increased insulin
dose, inadequate food intake, and skipped meals. Instruct patients on the management of hypoglycemia [see Warnings and
Precautions (5.3)].
Inform patients that their ability to concentrate and react may be impaired as a result of hypoglycemia. Advise patients who
have frequent hypoglycemia or reduced or absent warning signs of hypoglycemia to use caution when driving or operating machinery.

Medication Errors
Instruct patients to always check the insulin label before each injection to avoid mix-ups between insulin products [see
Warnings and Precautions (5.4)].

Hypersensitivity Reactions
Advise patients that hypersensitivity reactions have occurred with HUMULIN R. Inform patients on the symptoms of
hypersensitivity reactions and to seek medical attention if they occur [see Warnings and Precautions (5.5)].
Literature Revised: Month Year
Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, USA
Copyright © 1997, yyyy, Eli Lilly and Company. All rights reserved.
A8.0-LINR100-0000-USPI-YYYYMMDD

Reference ID: 4268906

 1
Patient Information
Humulin® (HU-mu-lin) R
insulin human injection
(100 units per mL)
Do not share your syringes with other people, even if the needle has been changed. You may give other
people a serious infection or get a serious infection from them.
What is Humulin R?
• Humulin R is a man-made insulin that is used to control high blood sugar in adults and children with diabetes
mellitus.

Who should not use Humulin R?

Do not use Humulin R if you:
• are having an episode of low blood sugar (hypoglycemia).
• have an allergy to human insulin or any of the ingredients in Humulin R. See the end of this Patient Information
leaflet for a complete list of ingredients in Humulin R.
What should I tell my healthcare provider before using Humulin R?
Before using Humulin R, tell your healthcare provider about all your medical conditions including, if you:
• have liver or kidney problems.
• take other medicines, especially ones called TZDs (thiazolidinediones).
• have heart failure or other heart problems. If you have heart failure, it may get worse while you take TZDs with
Humulin R.
• are pregnant, planning to become pregnant. Talk with your healthcare provider about the best way to control your
blood sugar if you plan to become pregnant or while you are pregnant.
• are breast-feeding or plan to breastfeed. HUMULIN R may pass into your breast milk. Talk with your healthcare
provider about the best way to feed your baby while using HUMULIN R.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines,
vitamins, or herbal supplements.
Before you start using Humulin R, talk to your healthcare provider about low blood sugar and how to manage
it.
How should I use Humulin R?
• Read the detailed Instructions for Use that comes with your Humulin R.
• Use Humulin R exactly as your healthcare provider tells you to. Your healthcare provider should tell you how much
Humulin R to use and when to use it.
• Use Humulin R 30 minutes before eating a meal.
• Know the type, strength, and amount of insulin you use. Do not change the type, or amount of insulin you use
unless your healthcare provider tells you to. The amount of insulin and the best time for you to take your insulin
may need to change if you use different types of insulin.
• Check your insulin label each time you give your injection to make sure you are using the correct insulin.
• Inject Humulin R under your skin (subcutaneously). Do not inject Humulin R into your vein (intravenously) or
muscle (intramuscularly).
- Do not mix Humulin R with any other insulin except Humulin® N. If Humulin R is mixed with Humulin N,
Humulin R should be drawn into the syringe first. Inject immediately after mixing.
• Change (rotate) your injection site with each dose.
• Check your blood sugar levels. Ask your healthcare provider what your blood sugars should be and when you
should check your blood sugar levels.
Keep Humulin R and all medicines out of reach of children.
Your dose of Humulin R may need to change because of:
• change in level of physical activity or exercise, weight gain or loss, increased stress, illness, change in diet, or
because of other medicines you take

Reference ID: 4268906

 2
What should I avoid while using Humulin R?
While using Humulin R do not:
• drive or operate heavy machinery, until you know how Humulin R affects you.
• drink alcohol or use prescription or over-the-counter medicines that contain alcohol.
What are the possible side effects of Humulin R?
Humulin R may cause serious side effects that can lead to death, including:
• low blood sugar (hypoglycemia). Signs and symptoms of low blood sugar may include:
- dizziness or lightheadedness, sweating, confusion, headache, blurred vision, slurred speech, shakiness, fast
heartbeat, anxiety, irritability or mood changes, hunger.
- Your healthcare provider may prescribe a glucagon emergency kit so that others can give you an injection if
your blood sugar becomes too low (hypoglycemic) and you are unable to take sugar by mouth.
• severe allergic reaction (whole body reaction). Get medical help right away, if you have any of these signs
or symptoms of a severe allergic reaction:
- a rash over your whole body, have trouble breathing, a fast heartbeat, or sweating.
• low potassium in your blood (hypokalemia).
• heart failure. Taking certain diabetes pills called thiazolidinediones or “TZDs” with Humulin R may cause heart
failure in some people. This can happen even if you have never had heart failure or heart problems before. If you
already have heart failure, it may get worse while you take TZDs with Humulin R. Your healthcare provider should
monitor you closely while you are taking TZDs with Humulin R. Tell your healthcare provider if you have any new
or worse symptoms of heart failure including:
- shortness of breath, swelling of your ankles or feet, sudden weight gain
Treatment with TZDs and Humulin R may need to be adjusted or stopped by your healthcare provider if you have new
or worse heart failure.
Get emergency medical help if you have:
• severe hypoglycemia needing hospitalization or emergency room care, and be sure to tell the hospital staff the
units of Humulin R that your healthcare provider has prescribed for you.
• trouble breathing, shortness of breath, fast heartbeat, swelling of your face, tongue, or throat, sweating, extreme
drowsiness, dizziness, confusion.
The most common side effects of Humulin R include:
• low blood sugar (hypoglycemia), allergic reactions including reactions at your injection site, skin thickening or pits
at the injection site (lipodystrophy), weight gain, swelling (edema) in hands or feet, itching and rash.
These are not all of the possible side effects of Humulin R. Call your doctor for medical advice about side effects.
You may report side effects to FDA at 1-800-FDA-1088.
General Information about the safe and effective use of Humulin R
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use
Humulin R for a condition for which it was not prescribed. Do not give Humulin R to other people, even if they have
the same symptoms you have. It may harm them.
This Patient Information leaflet summarizes the most important information about Humulin R. If you would like more
information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information
about Humulin R that is written for healthcare providers. For more information go to www.humulin.com or call
1-800-LillyRx (1-800-545-5979).

What are the ingredients in Humulin R?

Active Ingredient: human insulin
Inactive ingredients: glycerin, metacresol, water for injection, sodium hydroxide and hydrochloric acid.
Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, USA
For more information about Humulin R go to www.humulin.com.
Copyright © 2007, yyyy, Eli Lilly and Company. All rights reserved.

This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: May 2018
A5.0-LINR100-0000-PPI-YYYYMMDD

Reference ID: 4268906

 1

Instructions for Use

Humulin® (HU-mu-lin) R
insulin human injection
vial (100 units/mL)
Read the Instructions for Use before you start taking HUMULIN R and each time you get a new
vial. There may be new information. This information does not take the place of talking to your
healthcare provider about your medical condition or your treatment.

Do not share your syringes with other people, even if the needle has been changed. You
may give other people a serious infection or get a serious infection from them.

Supplies needed to give your injection

• a HUMULIN® R vial
• a U-100 insulin syringe and needle
• 2 alcohol swabs
• 1 sharps container for throwing away used needles and syringes. See “Disposing of used
needles and syringes” at the end of these instructions.

Protective
Cap

Rubber
Stopper
(under Cap)

Preparing the Dose

• Wash your hands with soap and water.
• Check the HUMULIN R label to make sure you are taking the right type of insulin. This is
especially important if you use more than 1 type of insulin.
• Do not use HUMULIN R past the expiration date printed on the label or 31 days after you
first use it.
• Always use a new syringe or needle for each injection to help make sure the syringe
needle is sterile and to prevent blocked needles. Do not reuse or share your

Reference ID: 4268906

 2

syringes or needles with other people. You may give other people a serious
infection or get a serious infection from them.

Step 1:
Check the insulin. HUMULIN R solution should look clear
and colorless. Do not use HUMULIN R if it looks cloudy,
thick, slightly colored, or if you see particles in the solution.
Step 2:
If you are using a new HUMULIN R vial, flip off the plastic
protective Cap, but do not remove the Rubber Stopper.

Step 3:
Wipe the Rubber Stopper with an alcohol swab.

Step 4:
Hold the syringe with the needle pointing up. Pull down on
the Plunger until the tip of the Plunger reaches the line for
the number of units for your prescribed dose.

(Example Dose: 20 units

shown)

Step 5:
Push the needle through the Rubber Stopper of the vial.

Step 6:
Push the Plunger all the way in. This puts air into the vial.

Reference ID: 4268906

 3

Step 7:
Turn the vial and syringe upside down and slowly pull the
plunger down until the tip is a few units past the line for
your prescribed dose.

(Example Dose: 20 units

Plunger is shown at 24 units)

If there are air bubbles in the syringe, tap the syringe

gently a few times to let any air bubbles rise to the top.

Step 8:
Slowly push the Plunger up until the tip reaches the line for
your prescribed dose.
Check to make sure that you have the right dose.

(Example Dose: 20 units

shown)

Step 9:
Pull the syringe out of the vial’s Rubber Stopper.

If you use HUMULIN R with HUMULIN N:

• HUMULIN N is the only type of insulin that can be mixed with HUMULIN R. Do not mix
HUMULIN R with any other type of insulin.
• HUMULIN R should be drawn up into the syringe first, before you draw up Humulin N. Talk
to your healthcare provider if you are not sure about the right way to mix HUMULIN R and
HUMULIN N.
• Give your injection right away.

Giving your Injection

• Inject your insulin exactly as your healthcare provider has shown you
• Change (rotate) your injection site for each injection

Reference ID: 4268906

 4

Step 10:
Choose your injection site.
HUMULIN R is injected under the skin
(subcutaneously) of your stomach area (abdomen),
buttocks, upper legs or upper arms.
Wipe the skin with an alcohol swab. Let the injection
site dry before you inject your dose.

Step 11:
Insert the needle into your skin.

Step 12:
Push down on the Plunger to inject your dose.
The needle should stay in your skin for at least 5 seconds
to make sure you have injected all of your insulin dose.

Step 13:
Pull the needle out of your skin.
• You may see a drop of insulin at the needle tip. This
is normal and does not affect the dose you received.
• If you see blood after you take the needle out of your
skin, press the injection site with a piece of gauze or
an alcohol swab. Do not rub the area.
• Do not recap the needle. Recapping the needle can
lead to a needle stick injury.

Disposing of used needles and syringes:

• Put your used needles and syringes in a FDA-cleared sharps disposal container right away
after use. Do not throw away (dispose of) loose needles and syringes in your household
trash.
• If you do not have a FDA-cleared sharps disposal container, you may use a household
container that is:
- made of a heavy-duty plastic,
- can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to
come out,
- upright and stable during use,
- leak resistant, and

Reference ID: 4268906

 5

- properly labeled to warn of hazardous waste inside the container.

• When your sharps disposal container is almost full, you will need to follow your community
guidelines for the right way to dispose of your sharps disposal container. There may be
state or local laws about how you should throw away used needles and syringes. For more
information about safe sharps disposal, and for specific information about sharps disposal
in the state that you live in, go to the FDA’s website at:
http://www.fda.gov/safesharpsdisposal.
• Do not dispose of your used sharps disposal container in your household trash unless your
community guidelines permit this. Do not recycle your used sharps disposal container.
How should I store HUMULIN R?
All unopened vials:
• Store all unopened vials in the refrigerator at 36° to 46°F (2° to 8°C).
• Do not freeze. Do not use if it has been frozen.
• Keep away from heat and out of direct light.
• Unopened vials can be used until the expiration date on the carton and label, if they have
been stored in the refrigerator.
• Unopened vials should be thrown away after 31 days if they are stored at room
temperature
After vials have been opened:
• Store opened vials in the refrigerator or at room temperature below 86°F (30°C) for up to
31 days.
• Keep away from heat and out of direct light.
• Throw away all opened vials after 31 days, even if there is still insulin left in the vial.
General information about the safe and effective use
• Keep HUMULIN R vials, syringes, needles, and all medicines out of the reach of children.
• Always use a new syringe or needle for each injection.
• Do not reuse or share your syringes or needles with other people. You may give
other people a serious infection or get a serious infection from them.
If you have any questions or problems with your HUMULIN, contact Lilly at 1-800-Lilly-Rx
(1-800-545-5979) or call your healthcare provider for help. For more information on HUMULIN
and insulin, go to www.humulin.com.

Scan this code to launch the humulin.com website

This Instructions for Use has been approved by the U.S. Food and Drug Administration.

Reference ID: 4268906

 6

Humulin® is a trademark of Eli Lilly and Company.

Instructions for Use revised: May 2018
Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, USA
Copyright © 1997, YYYY, Eli Lilly and Company. All rights reserved.

A4.0-LINR100VL-0001-IFU-YYYYMMDD

Reference ID: 4268906